GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioSig Technologies Inc (NAS:BSGM) » Definitions » Cash Conversion Cycle

BSGM (BioSig Technologies) Cash Conversion Cycle : 666.83 (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is BioSig Technologies Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

BioSig Technologies's Days Sales Outstanding for the three months ended in Dec. 2024 was 666.83.
BioSig Technologies's Days Inventory for the three months ended in Dec. 2024 was 0.
BioSig Technologies's Days Payable for the three months ended in Dec. 2024 was 0.
Therefore, BioSig Technologies's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2024 was 666.83.


BioSig Technologies Cash Conversion Cycle Historical Data

The historical data trend for BioSig Technologies's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSig Technologies Cash Conversion Cycle Chart

BioSig Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2,429.36 7,109.78 334.58 606.81

BioSig Technologies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 144.48 123.84 238.65 - 666.83

Competitive Comparison of BioSig Technologies's Cash Conversion Cycle

For the Medical Devices subindustry, BioSig Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSig Technologies's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioSig Technologies's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where BioSig Technologies's Cash Conversion Cycle falls into.


;
;

BioSig Technologies Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

BioSig Technologies's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=606.81+0-0
=606.81

BioSig Technologies's Cash Conversion Cycle for the quarter that ended in Dec. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=666.83+0-0
=666.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioSig Technologies  (NAS:BSGM) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


BioSig Technologies Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of BioSig Technologies's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSig Technologies Business Description

Traded in Other Exchanges
N/A
Address
55 Greens Farms Road, 1st Floor, Westport, CT, USA, 06880
BioSig Technologies Inc is a commercial-stage medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), It is committed to addressing healthcare's biggest priorities saving time, saving costs, and saving lives. Its first product, the PURE EP System, is an FDA-cleared non-invasive class II device consisting of a unique combination of hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals paving the way for personalized patient care.
Executives
Kenneth L Londoner director, 10 percent owner 10 RED COAT ROAD, WESTPORT CT 06880
Steven J Buhaly officer: Chief Financial Officer 1195 NW LOMPTON DRIVE, BEAVESTON OR 97006
John Sieckhaus officer: Chief Operating Officer C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
Steve Chaussy officer: Chief Financial Officer 9780 E AVE, HESPERIA CA 92345
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Gray Fleming officer: Chief Commercial Officer C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT CT 06880
James L Klein director 2300NE BROOKWOOD PKWY, HILLSBORO OR 97124
Frederick Hrkac director C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Jeffrey F Odonnell director 126 ROSSMORE DRIVE, MALVERN PA 19355
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Martha Pease director 33 SEAVIEW, MADISON CT 06443
John M Kowalski officer: VP of Sales 54 WILTON ROAD, 2ND FLOOR, WESTPORT CT 06880
Samuel E Navarro director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044

BioSig Technologies Headlines

From GuruFocus

BioSig Announces New Advisory Board Member Lorraine Spurge

By sperokesalga sperokesalga 03-24-2023